Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dosage Regimens: Designs and Approaches01:28

Dosage Regimens: Designs and Approaches

Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses01:25

Determination of Multiple Dosing Parameters: Loading and Maintenance Doses

A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
Dosage Regimen Designs: Nomograms and Tabulations01:23

Dosage Regimen Designs: Nomograms and Tabulations

Nomograms and tabulations are vital tools used by clinicians to design accurate and individualized dosage regimens. These instruments provide a straightforward method for adjusting dosages based on individual patient characteristics, including age, weight, and physiological condition. The foundation of a drug's nomogram is population pharmacokinetic data collected and analyzed using specific models. This data simplifies complex equations, presenting them diagrammatically or tabularly for easy...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Overview of dose-finding designs and trials in cell and gene therapies.

Journal of biopharmaceutical statistics·2026
Same author

Health-Related Quality of Life and Family Impact Among Children with Epilepsy: The Role of Seizure Control.

Neuroepidemiology·2026
Same author

Unilateral biportal endoscopy versus percutaneous endoscopic lumbar discectomy for far lateral disc herniation: a comparative study of clinical efficacy and learning curves.

BMC musculoskeletal disorders·2026
Same author

Endoscopic posterior cervical canal decompression versus laminoplasty for two-level cervical spondylotic myelopathy: clinical outcomes and finite element analysis.

Journal of orthopaedic surgery and research·2026
Same author

CUI-MET: A Clinical Utility Index Based Analysis and Decision Framework for Dose Optimization in Multiple-Dose, Multiple-Outcome Randomized Trials.

Pharmaceutical statistics·2026
Same author

Human parvovirus B19-associated Guillain-Barré syndrome diagnosed by cerebrospinal fluid targeted next-generation sequencing: a case report and literature review.

BMC infectious diseases·2026

Related Experiment Video

Updated: Jul 2, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

Implementing Project Optimus in Oncology Dosage Optimization: Where are We Now?

Revathi Ananthakrishnan1, Patrick Mitchell2, Dong Xi3

  • 1Bristol-Myers Squibb (BMS), Princeton, NJ, USA.

Therapeutic Innovation & Regulatory Science
|July 1, 2026
PubMed
Summary

Optimizing oncology drug dosage is crucial due to toxicity. A survey shows a shift from maximum tolerated dose to integrated strategies balancing efficacy, safety, and patient experience for better cancer drug development.

Keywords:
Dosage optimizationEfficacyPK/PDPRORandomized trial comparing dosesTotality of dataToxicity

More Related Videos

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
06:20

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Published on: March 11, 2021

An Open-Source Normothermic Perfusion System Designed for Research Scientists
11:23

An Open-Source Normothermic Perfusion System Designed for Research Scientists

Published on: July 18, 2025

Related Experiment Videos

Last Updated: Jul 2, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
06:20

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Published on: March 11, 2021

An Open-Source Normothermic Perfusion System Designed for Research Scientists
11:23

An Open-Source Normothermic Perfusion System Designed for Research Scientists

Published on: July 18, 2025

Area of Science:

  • Oncology Drug Development
  • Clinical Trial Design
  • Biostatistics

Background:

  • Optimal oncology drug dosing is critical due to high anticancer agent toxicity.
  • The "more is better" approach is challenged by targeted therapies and immunotherapies.
  • The U.S. Food and Drug Administration (FDA) initiated Project Optimus to enhance patient-centered dosage optimization.

Purpose of the Study:

  • To investigate current practices and challenges in oncology drug dosage optimization.
  • To understand how industry sponsors are implementing FDA guidance on dosage optimization.
  • To identify key areas for improvement in early-phase oncology trial design and execution.

Main Methods:

  • An industry-wide survey was conducted among oncology statisticians in biopharmaceutical companies.
  • The survey focused on current approaches to dosage selection and optimization in oncology drug development.
  • Data analysis aimed to identify trends and challenges in translating regulatory recommendations into practice.

Main Results:

  • A significant shift was observed away from solely relying on the maximum tolerated dose (MTD).
  • Integrated strategies balancing efficacy, safety, pharmacokinetics, and patient experience are increasingly adopted.
  • Challenges persist in applying FDA guidance due to developmental complexities and early-phase trial limitations.

Conclusions:

  • Cross-functional collaboration between statisticians and other team members is essential for early-phase trials.
  • Adoption of innovative trial designs can improve dosage optimization strategies.
  • Proactive regulatory engagement is recommended for successful oncology drug development and dosage optimization.